Morgan Stanley’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Morgan Stanley’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-13,723	Closed	-$499K	–	6713
2016 Q4	$499K	Buy	13,723 +986	+8%	+$34.9K	﹤0.01%	4933
2016 Q3	$486K	Buy	12,737 +12,237	+2,447%	+$181K	﹤0.01%	4541
2016 Q2	$4K	Sell	500 -9,300	-95%	-$62.5K	﹤0.01%	6279
2016 Q1	$61K	Buy	9,800 +7,500	+326%	+$46.9K	﹤0.01%	5530
2015 Q4	$19K	Buy	2,300 +1,800	+360%	+$9.47K	﹤0.01%	6060
2015 Q3	$2K	Sell	500 -5,912	-92%	-$43.7K	﹤0.01%	6505
2015 Q2	$57K	Buy	+6,412	New	+$55K	﹤0.01%	5815

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Morgan Stanley's CLCD Position: Q1 2017 in Review

Morgan Stanley sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 13,723 shares — an estimated $499K sold.

Morgan Stanley first reported a position in CLCD in Q2 2015 and held it in 7 quarters. The position peaked at $499K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Morgan Stanley reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Morgan Stanley sold 13,723 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $499K.
Morgan Stanley first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Morgan Stanley's CoLucid Pharmaceuticals, Inc. position peaked at $499K in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Morgan Stanley's 13F filing for Q1 2017, filed 12 May 2017.